Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3

Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value

$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

KPIs

Operating metrics that drive Johnson & Johnson's business · fiscal year ends 52/53-week fiscal year ending on the Sunday nearest December 31 (FY2025 ended December 28, 2025; Q3 2026 ended September 27, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q3 2026 2026-09-30	Q2 2026 2026-06-28	Q1 2026 2026-03-29	Q4 2025 2025-12-28	Q3 2025 2025-09-28	Q2 2025 2025-06-29	Q1 2025 2025-03-30	Q4 2024 2024-12-29	Q3 2024 2024-09-29	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31

Consolidated sales to customers ($M)($M)3	25,399	25,310	24,062	24,564	23,993	23,743	21,893	22,520	22,471	22,447	21,383	21,395
Geographic sales — United States ($M)($M)1	14,959	14,533	13,330	14,195	13,708	13,544	12,305	13,204	12,909	12,569	11,620	12,009
U.S. reported & operational sales growth YoY (%)(%)	9.1%	7.3%	8.3%	7.5%	6.2%	7.8%	5.9%	10.0%	7.6%	7.8%	7.8%	11.0%
Geographic sales — International ($M)($M)6	10,440	10,777	10,732	10,369	10,285	10,199	9,588	9,316	9,562	9,878	9,763	9,386
Europe sales ($M)($M)3	5,405	5,726	5,848	5,598	5,440	5,387	5,110	4,921	4,914	5,214	5,163	4,962
Europe reported sales growth YoY (%)(%)	-0.6%	6.3%	14.5%	13.8%	10.7%	3.3%	-1.0%	-0.8%	4.0%	1.6%	-7.6%	-3.2%
Europe operational (constant-currency) sales growth YoY (%)(%)	1.0%	3.3%	2.7%	5.2%	4.4%	-1.9%	2.2%	-0.2%	3.0%	3.4%	-7.7%	-5.8%
Europe currency (FX) impact YoY (%)(%)	-1.6%	3.0%	11.8%	8.6%	6.3%	5.2%	-3.2%	-0.6%	1.0%	-1.8%	0.1%	2.6%
Western Hemisphere excluding U.S. sales ($M)($M)3	1,385	1,309	1,293	1,271	1,231	1,206	1,167	1,135	1,173	1,212	1,194	1,166
Western Hemisphere ex-U.S. reported sales growth YoY (%)(%)	12.5%	8.5%	10.8%	12.0%	4.9%	-0.5%	-2.3%	-2.7%	0.3%	6.7%	11.0%	14.0%
Western Hemisphere ex-U.S. operational sales growth YoY (%)(%)	8.0%	2.7%	2.5%	11.0%	7.3%	6.2%	9.2%	17.6%	20.3%	22.6%	21.3%	18.1%
Western Hemisphere ex-U.S. currency (FX) impact YoY (%)(%)	4.5%	5.8%	8.3%	1.0%	-2.4%	-6.7%	-11.5%	-20.3%	-20.0%	-15.9%	-10.3%	-4.1%
Asia-Pacific, Africa sales ($M)($M)3	3,650	3,742	3,591	3,500	3,614	3,606	3,311	3,260	3,475	3,452	3,406	3,258
Asia-Pacific, Africa reported sales growth YoY (%)(%)	1.0%	3.8%	8.5%	7.4%	4.0%	4.4%	-2.8%	0.1%	0.5%	-4.0%	-1.1%	9.7%
Asia-Pacific, Africa operational sales growth YoY (%)(%)	1.0%	3.9%	6.1%	7.2%	3.4%	2.4%	-0.6%	0.9%	1.5%	1.9%	5.0%	12.1%
Asia-Pacific, Africa currency (FX) impact YoY (%)(%)	0.0%	-0.1%	2.4%	0.2%	0.6%	2.0%	-2.2%	-0.8%	-1.0%	-5.9%	-6.1%	-2.4%
International reported sales growth YoY (%)(%)	1.5%	5.7%	11.9%	11.3%	7.6%	3.2%	-1.8%	-0.7%	2.2%	0.2%	-3.4%	2.9%
International operational (constant-currency) sales growth YoY (%)(%)	1.8%	3.4%	3.9%	6.6%	4.4%	0.6%	2.1%	2.5%	4.6%	5.1%	-0.3%	2.7%
International currency (FX) impact YoY (%)(%)	-0.3%	2.3%	8.0%	4.7%	3.2%	2.6%	-3.9%	-3.2%	-2.4%	-4.9%	-3.1%	0.2%
Worldwide reported sales growth YoY (%)(%)3	5.9%	6.6%	9.9%	9.1%	6.8%	5.8%	2.4%	5.3%	5.2%	4.3%	2.3%	7.3%
Worldwide operational (constant-currency) sales growth YoY (%)(%)	6.0%	5.6%	6.4%	7.1%	5.4%	4.6%	4.2%	6.7%	6.3%	6.6%	3.9%	7.2%
Worldwide currency (FX) impact YoY (%)(%)	-0.1%	1.0%	3.5%	2.0%	1.4%	1.2%	-1.8%	-1.4%	-1.1%	-2.3%	-1.6%	0.1%
Worldwide adjusted operational sales growth ex-A&D YoY (%)(%)	6.1%	5.7%	5.3%	6.1%	4.4%	3.0%	3.3%	5.7%	5.4%	6.5%	4.0%	5.7%

Innovative Medicine Segment Total — Worldwide sales ($M)($M)7	16,757	16,384	15,426	15,763	15,563	15,202	13,873	14,332	14,580	14,490	13,562	13,722
Innovative Medicine Segment Total — U.S. sales ($M)($M)1	10,447	9,979	8,871	9,689	9,402	9,161	8,092	8,977	8,871	8,510	7,612	8,079
Innovative Medicine Segment Total — U.S. operational growth YoY (%)(%)	11.1%	8.9%	9.6%	7.9%	6.0%	7.6%	6.3%	11.1%	7.5%	8.9%	8.4%	9.5%
Innovative Medicine Segment Total — International sales ($M)($M)1	6,310	6,405	6,555	6,074	6,161	6,041	5,781	5,355	5,709	5,980	5,950	5,643
Innovative Medicine Segment Total — International operational growth YoY (%)(%)	3.0%	3.6%	4.3%	7.9%	4.3%	-1.6%	1.5%	-1.0%	4.4%	6.4%	-4.0%	-3.1%
Innovative Medicine Segment Total — Worldwide reported growth YoY (%)(%)	7.7%	7.8%	11.2%	10.0%	6.8%	4.9%	2.3%	4.4%	4.9%	5.5%	1.1%	4.2%
Innovative Medicine Segment Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	7.9%	6.8%	7.4%	7.9%	5.3%	3.8%	4.2%	6.1%	6.3%	7.8%	2.5%	4.0%
Innovative Medicine Segment Total — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	1.0%	3.8%	2.1%	1.5%	1.1%	-1.9%	-1.7%	-1.4%	-2.3%	-1.4%	0.2%
Innovative Medicine — Worldwide adjusted operational growth ex-A&D YoY (%)(%)	8.0%	6.9%	5.6%	6.2%	3.7%	2.4%	4.4%	6.3%	6.4%	8.0%	2.5%	4.0%
Oncology Therapeutic Area Total — Worldwide sales ($M)($M)13	7,602	7,406	6,973	6,861	6,529	6,312	5,678	5,497	5,380	5,090	4,814	4,618
Oncology Therapeutic Area Total — U.S. sales ($M)($M)1	4,267	4,069	3,615	3,793	3,468	3,385	3,013	3,019	2,816	2,636	2,383	2,285
Oncology Therapeutic Area Total — U.S. operational growth YoY (%)(%)	23.0%	20.3%	20.0%	25.6%	23.2%	28.4%	26.4%	32.2%	26.9%	27.4%	26.2%	23.0%
Oncology Therapeutic Area Total — International sales ($M)($M)1	3,335	3,337	3,358	3,069	3,060	2,928	2,664	2,476	2,565	2,455	2,430	2,334
Oncology Therapeutic Area Total — International operational growth YoY (%)(%)	9.5%	11.2%	15.3%	17.3%	14.8%	15.7%	14.4%	10.6%	14.3%	10.8%	12.6%	12.0%
Oncology Therapeutic Area Total — Worldwide reported growth YoY (%)(%)	16.4%	17.3%	22.8%	24.8%	21.3%	24.0%	17.9%	19.0%	18.7%	15.7%	17.1%	17.6%
Oncology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	16.7%	16.1%	17.8%	21.9%	19.2%	22.3%	20.4%	21.3%	20.5%	18.6%	18.8%	17.2%
Oncology Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)	-0.3%	1.2%	5.0%	2.9%	2.1%	1.7%	-2.5%	-2.3%	-1.8%	-2.9%	-1.7%	0.4%
DARZALEX (daratumumab) — Worldwide sales ($M)($M)4	4,239	4,207	3,964	3,903	3,672	3,539	3,237	3,084	3,016	2,878	2,692	2,550
DARZALEX (daratumumab) — U.S. sales ($M)($M)1	2,528	2,435	2,208	2,332	2,088	2,017	1,829	1,799	1,684	1,641	1,464	1,395
DARZALEX (daratumumab) — U.S. operational growth YoY (%)(%)	21.1%	20.7%	20.7%	29.6%	24.0%	23.0%	24.9%	28.9%	23.0%	24.2%	22.9%	22.5%
DARZALEX (daratumumab) — International sales ($M)($M)1	1,711	1,772	1,756	1,571	1,584	1,521	1,409	1,285	1,332	1,237	1,228	1,155
DARZALEX (daratumumab) — International operational growth YoY (%)(%)	8.5%	13.5%	14.0%	16.2%	14.7%	19.6%	19.8%	17.0%	22.8%	17.9%	19.0%	21.8%
DARZALEX (daratumumab) — Worldwide reported growth YoY (%)(%)	15.4%	18.9%	22.5%	26.6%	21.7%	23.0%	20.3%	20.9%	20.7%	18.4%	18.9%	22.4%
DARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	15.6%	17.6%	17.8%	24.1%	19.9%	21.5%	22.5%	23.5%	22.9%	21.3%	21.0%	22.2%
DARZALEX (daratumumab) — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	1.3%	4.7%	2.5%	1.8%	1.5%	-2.2%	-2.6%	-2.2%	-2.9%	-2.1%	0.2%
ERLEADA (apalutamide) — Worldwide sales ($M)($M)4	1,023	995	949	959	936	908	771	784	790	736	689	647
ERLEADA (apalutamide) — U.S. sales ($M)($M)1	423	396	342	405	378	378	292	342	337	318	285	287
ERLEADA (apalutamide) — U.S. operational growth YoY (%)(%)	11.8%	4.7%	17.3%	18.6%	12.3%	18.6%	2.5%	19.0%	17.1%	32.2%	14.1%	4.4%
ERLEADA (apalutamide) — International sales ($M)($M)1	600	599	607	554	558	530	479	442	453	418	404	361
ERLEADA (apalutamide) — International operational growth YoY (%)(%)	7.7%	9.7%	15.5%	17.5%	17.6%	22.8%	23.1%	25.7%	34.0%	32.8%	40.6%	34.0%
ERLEADA (apalutamide) — Worldwide reported growth YoY (%)(%)	9.4%	9.5%	23.1%	22.4%	18.4%	23.4%	11.9%	20.9%	25.4%	29.8%	27.0%	19.8%
ERLEADA (apalutamide) — Worldwide operational (constant-currency) growth YoY (%)(%)1	9.4%	7.6%	16.2%	18.0%	15.3%	21.0%	14.6%	22.7%	26.3%	32.5%	28.4%	19.0%
ERLEADA (apalutamide) — Worldwide currency (FX) impact YoY (%)(%)	0.0%	1.9%	6.9%	4.4%	3.1%	2.4%	-2.7%	-1.8%	-0.9%	-2.7%	-1.4%	0.8%
CARVYKTI (ciltacabtagene autoleucel) — Worldwide sales ($M)($M)4	710	657	597	555	524	439	369	334	286	186	157	159
CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M)($M)1	472	472	433	420	396	358	318	304	258	167	140	145
CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%)(%)	19.4%	31.7%	36.2%	38.2%	53.3%				84.9%	46.5%	99.8%
CARVYKTI (ciltacabtagene autoleucel) — International sales ($M)($M)	238	185	164	135	128	81	51	31	27	20	16	13
CARVYKTI (ciltacabtagene autoleucel) — Worldwide reported growth YoY (%)(%)	35.5%	49.4%	62.1%	65.8%	83.5%				87.7%	59.8%
CARVYKTI (ciltacabtagene autoleucel) — Worldwide operational (constant-currency) growth YoY (%)(%)1	35.2%	47.7%	57.4%	63.2%	81.4%				87.6%	59.9%
CARVYKTI (ciltacabtagene autoleucel) — Worldwide currency (FX) impact YoY (%)(%)	0.3%	1.7%	4.7%	2.6%	2.1%				0.1%	-0.1%
IMBRUVICA (ibrutinib) — Worldwide sales ($M)($M)4	563	599	660	684	695	735	709	731	753	770	784	788
IMBRUVICA (ibrutinib) — U.S. sales ($M)($M)1	145	149	143	207	211	239	235	250	259	246	265	255
IMBRUVICA (ibrutinib) — U.S. operational growth YoY (%)(%)	-31.6%	-37.6%	-39.1%	-17.4%	-18.3%	-2.7%	-11.5%	-2.0%	-1.9%	-6.4%	-1.5%	-19.8%
IMBRUVICA (ibrutinib) — International sales ($M)($M)1	420	449	517	478	483	496	474	481	494	525	518	533
IMBRUVICA (ibrutinib) — International operational growth YoY (%)(%)	-12.6%	-11.8%	-1.4%	-7.5%	-6.6%	-8.4%	-4.2%	-6.8%	-7.2%	-5.6%	-5.6%	-3.8%
IMBRUVICA (ibrutinib) — Worldwide reported growth YoY (%)(%)	-18.8%	-18.6%	-6.9%	-6.5%	-7.8%	-4.5%	-9.5%	-7.2%	-6.8%	-8.5%	-5.2%	-8.9%
IMBRUVICA (ibrutinib) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-18.4%	-20.2%	-13.9%	-10.9%	-10.6%	-6.6%	-6.7%	-5.2%	-5.5%	-5.9%	-4.3%	-9.7%
IMBRUVICA (ibrutinib) — Worldwide currency (FX) impact YoY (%)(%)	-0.4%	1.6%	7.0%	4.4%	2.8%	2.1%	-2.8%	-2.0%	-1.3%	-2.6%	-0.9%	0.8%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M)($M)4	320	289	257	216	198	179	141	122	89	69	47
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. sales ($M)($M)1	201	190	175	146	136	139	113	101	68	52	36
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%)(%)	47.9%	36.8%	55.1%	45.6%	99.7%		68.0%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — International sales ($M)($M)	119	99	82	70	61	41	28	21	21	17	11
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide reported growth YoY (%)(%)	62.3%	60.8%	82.7%	78.0%			69.0%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide operational (constant-currency) growth YoY (%)(%)1	63.5%	61.6%	80.5%	76.5%			89.0%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide currency (FX) impact YoY (%)(%)	-1.2%	-0.8%	2.2%	1.5%			122.0%
TECVAYLI (teclistamab) — Worldwide sales ($M)($M)4	312	260	202	176	177	166	151	146	135	135	133	126
TECVAYLI (teclistamab) — U.S. sales ($M)($M)	236	186	127	110	115	114	105	108	105	104	101	102
TECVAYLI (teclistamab) — International sales ($M)($M)1	77	74	74	66	62	52	46	38	30	30	33	24
TECVAYLI (teclistamab) — International operational growth YoY (%)(%)	25.9%	39.2%	52.1%	65.1%		72.0%	45.9%	71.6%	59.4%		19.0%
TECVAYLI (teclistamab) — Worldwide reported growth YoY (%)(%)	76.6%	56.5%	33.5%	20.8%	31.3%	23.1%	13.3%	15.8%	20.6%	42.9%	94.0%
TECVAYLI (teclistamab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	77.3%	56.1%	30.1%	18.9%	29.9%	22.4%	15.0%	18.0%	21.4%	43.5%	112.0%
TECVAYLI (teclistamab) — Worldwide currency (FX) impact YoY (%)(%)	-0.7%	0.4%	3.4%	1.9%	1.4%	0.7%	-1.7%	-2.2%	-0.8%	-0.6%	126.0%
TALVEY (talquetamab) — Worldwide sales ($M)($M)4	171	174	152	149	122	106	86	85	75	69	58
TALVEY (talquetamab) — U.S. sales ($M)($M)1	112	112	101	105	85	82	68	68	64	59	50
TALVEY (talquetamab) — U.S. operational growth YoY (%)(%)	31.6%	36.2%	48.5%	53.8%	34.2%	38.0%	35.2%
TALVEY (talquetamab) — International sales ($M)($M)	59	62	51	44	37	24	18	17	12	9	8
TALVEY (talquetamab) — Worldwide reported growth YoY (%)(%)	40.9%	63.3%	76.7%	75.8%	60.8%	55.0%	48.4%
TALVEY (talquetamab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	42.1%	62.6%	72.8%	73.1%	59.1%	54.3%	50.2%
TALVEY (talquetamab) — Worldwide currency (FX) impact YoY (%)(%)	-1.2%	0.7%	3.9%	2.7%	1.7%	0.7%	-1.8%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide sales ($M)($M)4				119	113	145	125	135	150	165	181	201
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — U.S. sales ($M)($M)1				5	5	6	7	9	5	11	9	9
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — U.S. operational growth YoY (%)(%)				-41.4%	-25.0%	-38.9%	-24.3%	-7.3%	-66.0%	21.6%	-41.3%	-52.0%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — International sales ($M)($M)1				115	108	139	118	127	144	154	172	191
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — International operational growth YoY (%)(%)				-11.1%	-26.8%	-13.3%	-28.5%	-30.7%	-24.4%	-23.6%	-20.7%	-23.2%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide reported growth YoY (%)(%)				-11.9%	-25.1%	-11.6%	-30.9%	-32.4%	-30.0%	-27.7%	-25.9%	-25.6%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide operational (constant-currency) growth YoY (%)(%)1				-13.0%	-26.8%	-14.9%	-28.3%	-29.6%	-27.5%	-21.9%	-22.1%	-25.3%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide currency (FX) impact YoY (%)(%)				1.1%	1.7%	3.3%	-2.6%	-2.8%	-2.5%	-5.8%	-3.8%	-0.3%
Other Oncology medicines — Worldwide sales ($M)($M)4	262	226	192	-283	207	238	214	75	86	83	73	-8
Other Oncology medicines — U.S. sales ($M)($M)	149	131	85	43	61	56	54	39	36	37	33	-32
Other Oncology medicines — International sales ($M)($M)1	111	97	106	-326	147	181	160	36	50	45	41	24
Other Oncology medicines — International operational growth YoY (%)(%)	-23.9%	-45.7%	-36.3%	3.0%	-25.6%	-12.3%	10.1%	30.6%	27.6%	-6.0%	-5.6%	28.4%
Other Oncology medicines — Worldwide reported growth YoY (%)(%)	26.3%	-4.6%	-10.6%	32.9%	9.7%	11.7%	21.7%	90.4%		84.2%	80.2%
Other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1	26.7%	-3.9%	-12.5%	30.3%	7.7%	9.7%	24.7%	92.4%		87.2%	80.5%
Other Oncology medicines — Worldwide currency (FX) impact YoY (%)(%)	-0.4%	-0.7%	1.9%	2.6%	2.0%	2.0%	-3.0%	-2.0%		-3.0%	-0.3%
Immunology Therapeutic Area Total — Worldwide sales ($M)($M)9	4,221	3,844	3,380	3,860	4,168	3,993	3,707	4,238	4,621	4,722	4,247	4,595
Immunology Therapeutic Area Total — U.S. sales ($M)($M)1	2,804	2,372	1,855	2,495	2,676	2,505	2,196	2,856	3,068	2,978	2,453	3,033
Immunology Therapeutic Area Total — U.S. operational growth YoY (%)(%)	4.8%	-5.3%	-15.5%	-12.6%	-12.8%	-15.9%	-10.5%	-5.9%	-3.9%	4.0%	0.2%	8.1%
Immunology Therapeutic Area Total — International sales ($M)($M)1	1,417	1,473	1,524	1,364	1,493	1,489	1,510	1,383	1,552	1,744	1,794	1,562
Immunology Therapeutic Area Total — International operational growth YoY (%)(%)	-4.8%	-3.5%	-6.4%	-5.5%	-6.3%	-16.2%	-11.5%	-6.5%	-2.1%	13.2%	11.0%	17.7%
Immunology Therapeutic Area Total — Worldwide reported growth YoY (%)(%)	1.3%	-3.7%	-8.8%	-8.9%	-9.8%	-15.4%	-12.7%	-7.8%	-4.7%	5.0%	3.3%	11.6%
Immunology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	1.4%	-4.6%	-11.8%	-10.3%	-10.6%	-16.0%	-10.9%	-6.1%	-3.3%	7.3%	4.6%	11.2%
Immunology Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)	-0.1%	0.9%	3.0%	1.4%	0.8%	0.6%	-1.8%	-1.7%	-1.4%	-2.3%	-1.3%	0.4%
TREMFYA (guselkumab) — Worldwide sales ($M)($M)4	2,396	2,046	1,608	1,589	1,424	1,186	956	949	1,007	906	808	910
TREMFYA (guselkumab) — U.S. sales ($M)($M)1	1,772	1,465	1,042	1,145	989	796	599	654	691	589	509	657
TREMFYA (guselkumab) — U.S. operational growth YoY (%)(%)	79.1%	84.2%	73.9%	75.1%	43.1%	35.2%	17.6%	-0.6%	9.1%	30.8%	25.4%	21.6%
TREMFYA (guselkumab) — International sales ($M)($M)1	624	581	566	445	434	391	356	295	316	317	299	252
TREMFYA (guselkumab) — International operational growth YoY (%)(%)	43.4%	44.2%	46.8%	44.0%	33.4%	20.5%	24.4%	21.7%	26.9%	30.5%	31.5%	17.8%
TREMFYA (guselkumab) — Worldwide reported growth YoY (%)(%)	68.3%	72.5%	68.3%	67.6%	41.3%	31.0%	18.2%	4.2%	13.0%	28.3%	26.3%	21.0%
TREMFYA (guselkumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	68.2%	71.0%	63.8%	65.4%	40.1%	30.1%	20.1%	5.6%	14.3%	30.7%	27.6%	20.5%
TREMFYA (guselkumab) — Worldwide currency (FX) impact YoY (%)(%)	0.1%	1.5%	4.5%	2.2%	1.2%	0.9%	-1.9%	-1.4%	-1.3%	-2.4%	-1.3%	0.5%
STELARA (ustekinumab) — Worldwide sales ($M)($M)4	716	740	656	1,230	1,570	1,653	1,625	2,349	2,676	2,885	2,451	2,753
STELARA (ustekinumab) — U.S. sales ($M)($M)1	368	336	220	766	1,022	1,078	981	1,699	1,770	1,855	1,396	1,786
STELARA (ustekinumab) — U.S. operational growth YoY (%)(%)	-64.0%	-68.8%	-77.6%	-54.9%	-42.3%	-41.9%	-29.8%	-4.9%	-7.5%	2.1%	-3.8%	10.1%
STELARA (ustekinumab) — International sales ($M)($M)1	349	404	435	462	549	575	644	650	906	1,030	1,055	967
STELARA (ustekinumab) — International operational growth YoY (%)(%)	-35.5%	-31.1%	-37.7%	-32.3%	-41.4%	-45.6%	-35.8%	-29.6%	-2.3%	10.1%	8.2%	23.9%
STELARA (ustekinumab) — Worldwide reported growth YoY (%)(%)	-54.4%	-55.2%	-59.7%	-47.7%	-41.3%	-42.7%	-33.7%	-14.7%	-6.6%	3.1%	0.3%	15.3%
STELARA (ustekinumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-54.0%	-55.7%	-61.7%	-48.6%	-42.0%	-43.2%	-32.3%	-13.6%	-5.7%	4.9%	1.1%	14.5%
STELARA (ustekinumab) — Worldwide currency (FX) impact YoY (%)(%)	-0.4%	0.5%	2.0%	0.9%	0.7%	0.5%	-1.4%	-1.1%	-0.9%	-1.8%	-0.8%	0.8%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide sales ($M)($M)4	568	618	647	632	687	690	659	583	516	537	554	502
SIMPONI / SIMPONI ARIA (golimumab) — U.S. sales ($M)($M)1	269	260	269	287	309	305	292	262	299	267	254	258
SIMPONI / SIMPONI ARIA (golimumab) — U.S. operational growth YoY (%)(%)	-13.2%	-14.6%	-7.8%	9.6%	3.6%	14.0%	14.8%	1.3%	-3.7%	-6.3%	-6.2%	-7.8%
SIMPONI / SIMPONI ARIA (golimumab) — International sales ($M)($M)1	299	358	378	345	377	387	366	321	218	270	299	244
SIMPONI / SIMPONI ARIA (golimumab) — International operational growth YoY (%)(%)	-20.3%	-9.5%	-4.1%	3.7%	69.8%	40.8%	29.7%	44.2%	-23.3%	22.8%	20.0%	11.8%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide reported growth YoY (%)(%)	-17.3%	-10.5%	-1.7%	8.4%	32.9%	28.6%	18.9%	16.2%	-18.0%	1.6%	3.0%	0.1%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-17.1%	-11.7%	-5.7%	6.4%	31.5%	27.5%	22.9%	22.1%	-13.6%	7.1%	6.8%	0.8%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	1.2%	4.0%	2.0%	1.4%	1.1%	-4.0%	-5.9%	-4.4%	-5.5%	-3.8%	-0.7%
REMICADE (infliximab) — Worldwide sales ($M)($M)5	394	338	422	370	476	455	467	359	419	393	434	429
REMICADE (infliximab) — U.S. sales ($M)($M)1	258	215	269	248	326	283	314	231	281	231	266	294
REMICADE (infliximab) — U.S. operational growth YoY (%)(%)	-20.8%	-24.1%	-14.4%	7.1%	16.2%	22.5%	18.1%	-21.4%	-5.4%	-16.7%	-3.9%	-7.4%
REMICADE (infliximab) — U.S. Exports ($M)($M)1	12	10	18	11	19	34	10	9	27	35	27	35
REMICADE (infliximab) — U.S. Exports growth YoY (%)(%)	-37.1%	-71.0%	78.6%	17.1%	-30.9%	-2.6%	-64.2%	-73.3%	-28.9%	7.9%	-32.7%	-15.1%
REMICADE (infliximab) — International sales ($M)($M)1	124	112	136	110	132	138	143	117	112	127	141	100
REMICADE (infliximab) — International operational growth YoY (%)(%)	-7.5%	-20.5%	-10.5%	-7.3%	16.7%	8.8%	6.8%	22.9%	-6.5%	-12.0%	-14.2%	-12.4%
REMICADE (infliximab) — Worldwide reported growth YoY (%)(%)	-17.3%	-25.8%	-9.5%	3.2%	13.6%	15.9%	7.5%	-16.5%	-9.1%	-14.9%	-10.9%	-9.6%
REMICADE (infliximab) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-17.6%	-26.4%	-11.2%	2.6%	13.3%	15.9%	9.3%	-15.0%	-7.7%	-13.4%	-9.9%	-9.4%
REMICADE (infliximab) — Worldwide currency (FX) impact YoY (%)(%)	0.3%	0.6%	1.7%	0.6%	0.3%	0.0%	-1.8%	-1.5%	-1.4%	-1.5%	-1.0%	-0.2%
Other Immunology medicines — Worldwide sales ($M)($M)2	147	104	46	40	12	8	1	0	1	2	0	2
Other Immunology medicines — U.S. sales ($M)($M)	126	85	38	38	12	8	1	0	1	2	0	2
Other Immunology medicines — International sales ($M)($M)	21	18	9	2	0	0	0	0	0	0	0	0

Neuroscience Therapeutic Area Total — Worldwide sales ($M)($M)9	2,375	2,337	2,175	2,115	2,024	2,051	1,647	1,775	1,755	1,782	1,803	1,801
Neuroscience Therapeutic Area Total — U.S. sales ($M)($M)1	1,733	1,659	1,494	1,439	1,367	1,377	968	1,148	1,094	1,102	1,054	1,022
Neuroscience Therapeutic Area Total — U.S. operational growth YoY (%)(%)	26.8%	20.5%	54.3%	25.4%	25.0%	24.9%	-8.1%	12.3%	5.6%	7.1%
Neuroscience Therapeutic Area Total — International sales ($M)($M)1	642	678	681	675	658	674	679	628	662	679	749	780
Neuroscience Therapeutic Area Total — International operational growth YoY (%)(%)	-1.7%	-1.1%	-6.3%	4.3%	-2.6%	-2.6%	-5.5%	-16.8%	-3.9%	-6.0%	-4.4%	-2.0%
Neuroscience Therapeutic Area Total — Worldwide reported growth YoY (%)(%)	17.3%	14.0%	32.0%	19.1%	15.3%	15.1%	-8.6%	-1.5%	0.8%	-0.6%	0.0%	3.7%
Neuroscience Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	17.6%	13.4%	29.3%	17.9%	14.6%	14.4%	-7.0%	-0.3%	1.7%	1.5%	2.2%	5.4%
Neuroscience Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)	-0.3%	0.6%	2.7%	1.2%	0.7%	0.7%	-1.6%	-1.2%	-0.9%	-2.1%	-2.2%	-1.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M)($M)4	998	1,015	1,038	986	929	992	903	1,063	1,049	1,054	1,056	1,011
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. sales ($M)($M)1	739	738	758	704	664	732	625	796	780	784	765	733
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. operational growth YoY (%)(%)	11.4%	0.8%	21.2%	-11.5%	-14.9%	-6.7%	-18.2%	8.6%	6.8%	8.8%	7.2%	8.0%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — International sales ($M)($M)1	258	278	280	281	267	260	277	267	269	269	292	278
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — International operational growth YoY (%)(%)	-2.4%	5.1%	-4.9%	1.9%	-3.0%	-5.1%	-1.1%	-1.8%	-8.3%	-9.0%	-8.7%	-15.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide reported growth YoY (%)(%)	7.3%	2.3%	15.0%	-7.3%	-11.3%	-5.9%	-14.5%	5.1%	1.9%	2.2%	1.2%	0.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide operational (constant-currency) growth YoY (%)(%)1	7.5%	1.9%	13.2%	-8.2%	-11.9%	-6.3%	-13.5%	5.7%	2.4%	3.5%	2.2%	0.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	0.4%	1.8%	0.9%	0.6%	0.4%	-1.0%	-0.6%	-0.5%	-1.3%	-1.0%	0.0%
SPRAVATO (esketamine) — Worldwide sales ($M)($M)4	624	584	468	503	459	414	320	297	284	271	225	206
SPRAVATO (esketamine) — U.S. sales ($M)($M)1	559	514	406	438	405	366	276	269	243	226	191	180
SPRAVATO (esketamine) — U.S. operational growth YoY (%)(%)	37.9%	40.7%	47.0%	63.0%	67.1%	61.1%	45.0%	50.1%	56.8%	57.9%	71.5%	72.3%
SPRAVATO (esketamine) — International sales ($M)($M)1	66	70	61	64	53	50	43	28	42	44	34	26
SPRAVATO (esketamine) — International operational growth YoY (%)(%)	21.4%	34.7%	28.7%		23.8%	11.0%	31.7%	12.5%	47.4%	77.4%	74.8%	83.4%
SPRAVATO (esketamine) — Worldwide reported growth YoY (%)(%)	36.1%	40.8%	46.4%	69.0%	61.5%	53.3%	41.9%	44.6%	54.9%	60.2%	72.2%	74.1%
SPRAVATO (esketamine) — Worldwide operational (constant-currency) growth YoY (%)(%)1	36.0%	40.0%	44.5%	67.8%	60.8%	53.0%	42.9%	45.3%	55.3%	60.8%	72.0%	73.6%
SPRAVATO (esketamine) — Worldwide currency (FX) impact YoY (%)(%)	0.1%	0.8%	1.9%	1.2%	0.7%	0.3%	-1.0%	-0.7%	-0.4%	-0.6%	0.2%	0.5%
CAPLYTA (lumateperone) — Worldwide sales ($M)($M)2	398	361	270	249	240	211	0	0	0	0
CAPLYTA (lumateperone) — U.S. sales ($M)($M)	398	361	270	249	240	211	0	0	0	0
CAPLYTA (lumateperone) — International sales ($M)($M)	0	0	0	0	0	0	0	0	0	0
CONCERTA / methylphenidate — Worldwide sales ($M)($M)4	143	146	136	132	140	164	148	159	142	163	177	180
CONCERTA / methylphenidate — U.S. sales ($M)($M)1	6	12	22	6	14	24	38	33	26	34	41	39
CONCERTA / methylphenidate — U.S. operational growth YoY (%)(%)	-56.3%	-48.6%	-43.4%	-79.6%	-49.2%	-27.7%	-7.4%	-12.8%	-55.0%	-47.7%	-41.2%	5.7%
CONCERTA / methylphenidate — International sales ($M)($M)1	138	133	115	126	127	139	110	125	117	129	136	142
CONCERTA / methylphenidate — International operational growth YoY (%)(%)	8.9%	-4.8%	-0.6%	-1.4%	8.5%	7.0%	-15.2%	-7.7%	-8.5%	-4.6%	4.5%	9.2%
CONCERTA / methylphenidate — Worldwide reported growth YoY (%)(%)	2.1%	-10.8%	-8.0%	-17.1%	-1.4%	0.2%	-16.3%	-11.7%	-24.8%	-21.5%	-14.1%	7.4%
CONCERTA / methylphenidate — Worldwide operational (constant-currency) growth YoY (%)(%)1	2.9%	-11.3%	-11.7%	-17.8%	-1.8%	-0.2%	-13.4%	-8.8%	-22.5%	-17.9%	-11.1%	8.5%
CONCERTA / methylphenidate — Worldwide currency (FX) impact YoY (%)(%)	-0.8%	0.5%	3.7%	0.7%	0.4%	0.4%	-2.9%	-2.9%	-2.3%	-3.6%	-3.0%	-1.1%
Other Neuroscience medicines — Worldwide sales ($M)($M)4	212	232	262	245	256	270	277	255	281	294	345	404
Other Neuroscience medicines — U.S. sales ($M)($M)1	32	34	38	40	46	45	28	49	46	57	58	71
Other Neuroscience medicines — U.S. operational growth YoY (%)(%)	-30.6%	-22.9%	32.6%	-18.3%	0.4%	-23.5%	-50.6%	-31.0%	-51.4%	-42.5%	-31.1%	-23.0%
Other Neuroscience medicines — International sales ($M)($M)1	180	198	224	205	210	226	248	206	235	237	287	334
Other Neuroscience medicines — International operational growth YoY (%)(%)	-13.1%	-13.7%	-16.3%	-4.3%	-12.3%	-7.6%	-9.8%	-35.4%	-2.0%	-10.8%	-8.4%	3.2%
Other Neuroscience medicines — Worldwide reported growth YoY (%)(%)	-17.3%	-14.0%	-5.4%	-4.1%	-8.9%	-8.4%	-19.6%	-36.9%	-17.4%	-23.7%	-18.5%	-8.7%
Other Neuroscience medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1	-16.2%	-15.2%	-11.3%	-6.9%	-10.2%	-10.7%	-16.7%	-34.6%	-15.7%	-19.1%	-12.9%	-2.3%
Other Neuroscience medicines — Worldwide currency (FX) impact YoY (%)(%)	-1.1%	1.2%	5.9%	2.8%	1.3%	2.3%	-2.9%	-2.3%	-1.7%	-4.6%	-5.6%	-6.4%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M)($M)7	897	1,143	1,135	1,184	1,115	1,113	1,025	1,092	1,102	1,039	1,049	1,017
Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. sales ($M)($M)1	588	814	831	865	815	799	744	819	815	743	766	733
Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. operational growth YoY (%)(%)	-27.8%	1.8%	11.7%	5.7%	-0.1%	7.6%	-2.9%	11.6%	20.0%	8.7%	27.5%	20.2%
Pulmonary Hypertension (PH) Therapeutic Area Total — International sales ($M)($M)1	309	329	304	319	300	314	281	274	287	296	283	282
Pulmonary Hypertension (PH) Therapeutic Area Total — International operational growth YoY (%)(%)	4.1%	3.4%	1.0%	12.2%	2.0%	2.8%	3.2%	1.2%	9.7%	11.2%	10.9%	10.9%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide reported growth YoY (%)(%)	-19.5%	2.6%	10.7%	8.4%	1.1%	7.1%	-2.3%	7.4%	15.6%	6.9%	20.2%	16.7%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	-19.2%	2.2%	8.7%	7.4%	0.4%	6.2%	-1.2%	8.7%	17.0%	9.4%	22.4%	17.4%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)	-0.3%	0.4%	2.0%	1.0%	0.7%	0.9%	-1.1%	-1.3%	-1.4%	-2.5%	-2.2%	-0.7%
UPTRAVI (selexipag) — Worldwide sales ($M)($M)4	483	494	483	491	484	476	451	465	458	426	468	419
UPTRAVI (selexipag) — U.S. sales ($M)($M)1	383	386	385	397	392	382	365	391	379	349	392	348
UPTRAVI (selexipag) — U.S. operational growth YoY (%)(%)	-2.2%	1.0%	5.4%	1.6%	3.5%	9.4%	-6.9%	12.3%	12.7%	3.3%	29.0%	24.3%
UPTRAVI (selexipag) — International sales ($M)($M)1	100	108	98	94	92	94	86	75	80	76	76	70
UPTRAVI (selexipag) — International operational growth YoY (%)(%)	8.4%	10.1%	5.1%	20.8%	12.0%	19.8%	17.5%	11.2%	28.2%	34.4%	38.6%	31.4%
UPTRAVI (selexipag) — Worldwide reported growth YoY (%)(%)	-0.1%	3.8%	7.1%	5.7%	5.6%	11.7%	-3.6%	11.2%	14.2%	6.6%	29.2%	24.6%
UPTRAVI (selexipag) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-0.2%	2.8%	5.4%	4.7%	5.0%	11.3%	-2.9%	12.1%	15.2%	8.1%	30.5%	25.4%
UPTRAVI (selexipag) — Worldwide currency (FX) impact YoY (%)(%)	0.1%	1.0%	1.7%	1.0%	0.6%	0.4%	-0.7%	-0.9%	-1.0%	-1.5%	-1.3%	-0.8%
OPSUMIT / OPSYNVI (macitentan) — Worldwide sales ($M)($M)4	372	602	606	643	578	582	522	570	583	548	524	536
OPSUMIT / OPSYNVI (macitentan) — U.S. sales ($M)($M)1	193	416	433	458	409	403	363	408	417	376	356	368
OPSUMIT / OPSYNVI (macitentan) — U.S. operational growth YoY (%)(%)	-52.8%	3.2%	19.3%	11.9%	-1.6%	6.9%	2.1%	4.8%	25.4%	13.7%	30.4%	20.5%
OPSUMIT / OPSYNVI (macitentan) — International sales ($M)($M)1	179	187	172	185	168	180	159	162	166	171	169	169
OPSUMIT / OPSYNVI (macitentan) — International operational growth YoY (%)(%)	7.8%	3.6%	1.7%	10.9%	-1.8%	2.1%	-2.5%	-2.5%	1.7%	0.5%	4.6%	8.3%
OPSUMIT / OPSYNVI (macitentan) — Worldwide reported growth YoY (%)(%)	-35.7%	3.4%	16.1%	12.7%	-0.8%	6.4%	-0.5%	1.7%	16.8%	7.1%	19.1%	16.2%
OPSUMIT / OPSYNVI (macitentan) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-35.2%	3.3%	14.0%	11.6%	-1.7%	5.4%	0.6%	2.5%	17.4%	9.1%	20.6%	16.3%
OPSUMIT / OPSYNVI (macitentan) — Worldwide currency (FX) impact YoY (%)(%)	-0.5%	0.1%	2.1%	1.1%	0.9%	1.0%	-1.1%	-0.8%	-0.6%	-2.0%	-1.5%	-0.1%
Other Pulmonary Hypertension medicines — Worldwide sales ($M)($M)4	42	47	46	49	53	55	52	57	60	67	56	61
Other Pulmonary Hypertension medicines — U.S. sales ($M)($M)1	12	13	12	10	13	16	15	19	21	17	18	18
Other Pulmonary Hypertension medicines — U.S. operational growth YoY (%)(%)	-7.3%	-16.9%	-21.1%	-43.7%	-36.5%	-12.4%	-12.7%		54.0%	18.8%	-24.6%	-29.4%
Other Pulmonary Hypertension medicines — International sales ($M)($M)1	30	34	34	39	39	40	37	38	39	49	39	45
Other Pulmonary Hypertension medicines — International operational growth YoY (%)(%)	-21.2%	-12.7%	-11.8%	1.2%	-2.5%	-21.3%	-0.3%	-0.4%	12.4%	21.0%	-1.0%	-3.9%
Other Pulmonary Hypertension medicines — Worldwide reported growth YoY (%)(%)	-19.7%	-15.0%	-12.1%	-12.5%	-13.1%	-16.9%	-7.2%	32.3%	15.0%	7.2%	-19.5%	-16.2%
Other Pulmonary Hypertension medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1	-17.7%	-13.9%	-14.5%	-13.5%	-14.1%	-19.0%	-4.3%	39.3%	25.9%	20.4%	-8.9%	-12.4%
Other Pulmonary Hypertension medicines — Worldwide currency (FX) impact YoY (%)(%)	-2.0%	-1.1%	2.4%	1.0%	1.0%	2.1%	-2.9%	-7.0%	-10.9%	-13.2%	-10.6%	-3.8%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M)($M)8	813	763	889	807	829	803	802	774	836	965	821	852
Infectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M)($M)1	317	300	342	303	326	320	315	331	365	334	324	353
Infectious Diseases (ID) Therapeutic Area Total — U.S. operational growth YoY (%)(%)	-2.7%	-6.3%	8.6%	-8.5%	-10.5%	-4.3%	-2.8%	-6.4%	1.5%	-15.4%	-17.4%	-14.6%
Infectious Diseases (ID) Therapeutic Area Total — International sales ($M)($M)1	496	463	547	505	501	484	487	443	471	631	497	498
Infectious Diseases (ID) Therapeutic Area Total — International operational growth YoY (%)(%)	-0.1%	-6.2%	1.3%	5.6%	0.5%	-26.8%	1.9%	-9.8%	-5.1%	-11.6%	-58.5%	-58.2%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide reported growth YoY (%)(%)	-1.8%	-5.0%	10.8%	4.3%	-0.9%	-16.8%	-2.2%	-9.2%	-2.7%	-13.9%	-48.3%	-44.7%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	-1.1%	-6.3%	4.1%	-0.4%	-4.3%	-19.0%	0.1%	-8.4%	-2.4%	-12.9%	-48.3%	-46.5%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)	-0.7%	1.3%	6.7%	4.7%	3.4%	2.2%	-2.3%	-0.8%	-0.3%	-1.0%	0.0%	1.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide sales ($M)($M)4	381	372	443	383	397	396	403	407	449	438	418	439
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. sales ($M)($M)1	307	296	334	294	315	312	305	321	355	321	314	341
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. operational growth YoY (%)(%)	-2.5%	-5.1%	9.5%	-8.4%	-11.0%	-3.0%	-2.9%	-5.8%	2.8%	-16.0%	-16.9%	-14.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International sales ($M)($M)1	74	76	109	89	81	85	98	86	94	117	104	98
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International operational growth YoY (%)(%)	-7.7%	-12.8%	0.7%	-2.9%	-18.5%	-29.4%	-0.6%	-8.9%	-3.0%	9.9%	5.5%	-0.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide reported growth YoY (%)(%)	-3.8%	-6.3%	10.0%	-5.8%	-11.6%	-9.4%	-3.7%	-7.4%	0.6%	-11.0%	-12.3%	-11.0%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-3.6%	-6.8%	7.4%	-7.2%	-12.6%	-10.0%	-2.3%	-6.5%	1.5%	-10.3%	-12.3%	-11.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	0.5%	2.6%	1.4%	1.0%	0.6%	-1.4%	-0.9%	-0.9%	-0.7%	0.0%	0.8%
EDURANT / rilpivirine — Worldwide sales ($M)($M)4	386	350	409	383	385	360	358	322	330	297	323	307
EDURANT / rilpivirine — U.S. sales ($M)($M)1	5	3	7	5	7	6	8	7	8	8	8	9
EDURANT / rilpivirine — U.S. operational growth YoY (%)(%)	-31.6%	-49.6%	-13.1%	-39.1%	-7.9%	-25.4%	-1.3%	-10.1%	-15.8%	-2.8%	-10.9%	-12.4%
EDURANT / rilpivirine — International sales ($M)($M)1	382	347	402	379	378	354	350	315	323	288	315	299
EDURANT / rilpivirine — International operational growth YoY (%)(%)	2.4%	-3.8%	3.2%	11.1%	9.9%	16.7%	14.7%	5.6%	11.4%	13.0%	15.7%	1.5%
EDURANT / rilpivirine — Worldwide reported growth YoY (%)(%)	0.4%	-2.7%	14.1%	19.2%	16.4%	21.6%	10.7%	4.6%	11.5%	11.0%	15.7%	5.8%
EDURANT / rilpivirine — Worldwide operational (constant-currency) growth YoY (%)(%)1	1.8%	-4.6%	2.8%	9.9%	9.5%	15.5%	14.3%	5.1%	10.6%	12.5%	14.8%	1.0%
EDURANT / rilpivirine — Worldwide currency (FX) impact YoY (%)(%)	-1.4%	1.9%	11.3%	9.3%	6.9%	6.1%	-3.6%	-0.5%	0.9%	-1.5%	0.9%	4.8%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M)($M)4								0	1	172	25	44
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — U.S. sales ($M)($M)								0	0	0	0	0
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M)($M)1								0	1	172	25	44
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%)(%)									-98.9%	-39.7%	-96.7%	-95.2%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%)(%)									-97.7%	-39.7%	-96.6%	-93.7%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide operational (constant-currency) growth YoY (%)(%)1									-98.9%	-39.7%	-96.7%	-95.2%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide currency (FX) impact YoY (%)(%)									1.2%	0.0%	0.1%	1.5%
Other Infectious Diseases medicines — Worldwide sales ($M)($M)4	46	41	37	40	47	47	41	45	56	233	78	1,179
Other Infectious Diseases medicines — U.S. sales ($M)($M)1	5	1	1	4	4	2	2	1	3	5	2	4
Other Infectious Diseases medicines — U.S. operational growth YoY (%)(%)	29.9%	-47.9%	-56.9%	92.9%	57.3%	-51.8%	7.7%	-53.1%	-52.2%	18.5%	-68.8%	-30.4%
Other Infectious Diseases medicines — International sales ($M)($M)1	40	40	36	37	42	45	39	43	54	227	77	1,175
Other Infectious Diseases medicines — International operational growth YoY (%)(%)	-7.9%	-12.8%	-14.7%	-18.0%	-22.3%	-80.6%	-47.0%	-22.4%	-20.5%	-21.1%	-30.6%	-4.9%
Other Infectious Diseases medicines — Worldwide reported growth YoY (%)(%)	-3.0%	-11.6%	-10.4%	-9.9%	-17.5%	-79.8%	-47.6%	-26.1%	-25.4%	-23.1%	-35.1%	-7.8%
Other Infectious Diseases medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1	-4.5%	-14.6%	-16.5%	-13.2%	-18.5%	-79.9%	-45.9%	-24.4%	-22.9%	-18.8%	-33.1%	-7.1%
Other Infectious Diseases medicines — Worldwide currency (FX) impact YoY (%)(%)	1.5%	3.0%	6.1%	3.3%	1.0%	0.1%	-1.7%	-1.7%	-2.5%	-4.3%	-2.0%	-0.7%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide sales ($M)($M)6	849	889	876	936	899	930	1,013	957	884	892	829	837
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. sales ($M)($M)1	736	765	734	794	750	776	855	805	713	717	631	652
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. operational growth YoY (%)(%)	-1.9%	-1.3%	-14.2%	-1.4%	5.3%	8.2%	35.4%	23.3%	-6.5%	-7.7%	-11.7%	-15.9%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International sales ($M)($M)1	112	124	142	142	149	154	158	153	170	176	197	185
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International operational growth YoY (%)(%)	-23.8%	-21.5%	-17.5%	-10.7%	-15.6%	-13.2%	-15.3%	-15.1%	-10.0%	4.0%	-6.8%	-6.7%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide reported growth YoY (%)(%)	-5.6%	-4.3%	-13.6%	-2.2%	1.7%	4.2%	22.3%	14.3%	-7.6%	-6.2%	-10.6%	-13.7%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	-5.5%	-4.7%	-14.7%	-2.9%	1.2%	4.0%	23.4%	14.8%	-7.2%	-5.5%	-10.5%	-14.1%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)	-0.1%	0.4%	1.1%	0.7%	0.5%	0.2%	-1.1%	-0.5%	-0.4%	-0.7%	-0.1%	0.4%
XARELTO (rivaroxaban) — Worldwide sales ($M)($M)4	653	664	642	687	635	621	690	676	592	587	518	525
XARELTO (rivaroxaban) — U.S. sales ($M)($M)1	653	664	642	687	635	621	690	676	592	587	518	525
XARELTO (rivaroxaban) — U.S. operational growth YoY (%)(%)	2.7%	7.1%	-7.0%	1.7%	7.4%	5.6%	33.3%	28.5%	-5.2%	-7.9%	-10.4%	-21.2%
XARELTO (rivaroxaban) — International sales ($M)($M)1	0	0	0	0	0	0	0	0	0	0	0	0
XARELTO (rivaroxaban) — International operational growth YoY (%)(%)	-23.8%	-21.5%	-17.5%	-10.7%	-15.6%	-13.2%	-15.3%	-15.1%	-10.0%	4.0%	-6.8%	-6.7%
XARELTO (rivaroxaban) — Worldwide reported growth YoY (%)(%)	2.7%	7.1%	-7.0%	1.7%	7.4%	5.6%	33.3%	28.5%	-5.2%	-7.9%	-10.4%	-21.2%
XARELTO (rivaroxaban) — Worldwide operational (constant-currency) growth YoY (%)(%)1	2.7%	7.1%	-7.0%	1.7%	7.4%	5.6%	33.3%	28.5%	-5.2%	-7.9%	-10.4%	-21.2%
XARELTO (rivaroxaban) — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	1.1%	3.4%	2.4%	1.5%	0.5%	-2.8%	-1.5%	-1.1%	-1.9%	-0.1%	1.3%
Other Cardiovascular / Metabolism / Other medicines — Worldwide sales ($M)($M)2	197	225	233	249	264	309	323	281	292	305	311	312
Other Cardiovascular / Metabolism / Other medicines — U.S. sales ($M)($M)	84	101	91	107	115	155	165	130	121	129	114	127
Other Cardiovascular / Metabolism / Other medicines — International sales ($M)($M)	112	124	142	142	149	154	158	153	170	176	197	185

MedTech Segment Total — Worldwide sales ($M)($M)9	8,642	8,926	8,636	8,801	8,430	8,541	8,020	8,188	7,891	7,957	7,821	7,673
MedTech Segment Total — U.S. sales ($M)($M)1	4,512	4,554	4,459	4,506	4,306	4,383	4,213	4,227	4,038	4,059	4,008	3,930
MedTech Segment Total — U.S. operational growth YoY (%)(%)	4.8%	3.9%	5.9%	6.6%	6.6%	8.0%	5.1%	7.6%	7.8%	5.7%	6.6%	14.1%
MedTech Segment Total — International sales ($M)($M)1	4,130	4,372	4,177	4,295	4,124	4,158	3,807	3,961	3,853	3,898	3,813	3,743
MedTech Segment Total — International operational growth YoY (%)(%)	0.1%	3.2%	3.2%	4.9%	4.5%	4.1%	3.0%	7.6%	5.0%	3.2%	6.1%	12.8%
MedTech Segment Total — Worldwide reported growth YoY (%)(%)	2.5%	4.5%	7.7%	7.5%	6.8%	7.3%	2.5%	6.7%	5.8%	2.2%	4.5%	13.3%
MedTech Segment Total — Worldwide operational (constant-currency) growth YoY (%)(%)1	2.5%	3.6%	4.6%	5.8%	5.6%	6.1%	4.1%	7.6%	6.4%	4.4%	6.3%	13.4%
MedTech Segment Total — Worldwide currency (FX) impact YoY (%)(%)	0.0%	0.9%	3.1%	1.7%	1.2%	1.2%	-1.6%	-0.9%	-0.6%	-2.2%	-1.8%	-0.1%
MedTech — Worldwide adjusted operational growth ex-A&D YoY (%)(%)	2.5%	3.7%	4.7%	5.9%	5.7%	4.1%	1.3%	4.6%	3.7%	4.0%	6.5%	9.1%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M)($M)8	2,307	2,404	2,377	2,299	2,213	2,313	2,103	2,062	1,966	1,873	1,806	1,669
Cardiovascular (formerly Interventional Solutions) Franchise — U.S. sales ($M)($M)1	1,397	1,426	1,399	1,374	1,306	1,364	1,261	1,221	1,148	1,119	1,025	971
Cardiovascular (formerly Interventional Solutions) Franchise — U.S. operational growth YoY (%)(%)	7.0%	4.5%	10.9%	12.5%	13.8%	21.9%	23.0%	25.8%	28.6%	23.3%	18.8%	61.0%
Cardiovascular (formerly Interventional Solutions) Franchise — International sales ($M)($M)1	910	978	978	925	908	948	842	841	819	753	781	698
Cardiovascular (formerly Interventional Solutions) Franchise — International operational growth YoY (%)(%)	-0.2%	1.1%	9.9%	6.8%	8.4%	22.9%	10.7%	22.0%	23.7%	11.2%	27.6%	41.7%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide reported growth YoY (%)(%)	4.3%	4.0%	13.0%	11.5%	12.6%	23.5%	16.4%	23.6%	26.2%	15.6%	20.2%	51.9%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	4.1%	3.1%	10.5%	10.1%	11.6%	22.3%	17.7%	24.2%	26.5%	18.0%	22.5%	52.3%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide currency (FX) impact YoY (%)(%)	0.2%	0.9%	2.5%	1.4%	1.0%	1.2%	-1.3%	-0.6%	-0.3%	-2.4%	-2.3%	-0.4%
Electrophysiology sub-franchise — Worldwide sales ($M)($M)4	1,487	1,533	1,489	1,425	1,418	1,468	1,323	1,321	1,279	1,323	1,344	1,239
Electrophysiology sub-franchise — U.S. sales ($M)($M)1	771	783	736	746	720	741	684	681	660	705	692	667
Electrophysiology sub-franchise — U.S. operational growth YoY (%)(%)	7.0%	5.8%	7.6%	9.5%	9.1%	5.1%	-1.1%	2.1%	7.9%	15.7%	21.3%	22.0%
Electrophysiology sub-franchise — International sales ($M)($M)1	717	749	753	679	698	728	638	640	619	618	652	572
Electrophysiology sub-franchise — International operational growth YoY (%)(%)	1.8%	0.4%	11.7%	3.2%	10.4%	15.2%	0.7%	13.3%	13.8%	11.1%	30.9%	29.0%
Electrophysiology sub-franchise — Worldwide reported growth YoY (%)(%)	4.9%	4.4%	12.6%	7.9%	10.8%	11.0%	-1.6%	6.6%	10.2%	10.6%	23.0%	24.7%
Electrophysiology sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	4.4%	3.1%	9.5%	6.5%	9.7%	9.8%	-0.2%	7.3%	10.7%	13.4%	25.9%	25.2%
Electrophysiology sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	0.5%	1.3%	3.1%	1.4%	1.1%	1.2%	-1.4%	-0.7%	-0.5%	-2.8%	-2.9%	-0.5%
Abiomed (Impella heart pumps) sub-franchise — Worldwide sales ($M)($M)4	412	440	488	460	423	448	420	384	362	379	371	340
Abiomed (Impella heart pumps) sub-franchise — U.S. sales ($M)($M)1	335	342	389	358	336	360	339	308	293	309	303	276
Abiomed (Impella heart pumps) sub-franchise — U.S. operational growth YoY (%)(%)	-0.3%	-4.8%	14.5%	16.5%	14.5%	16.6%	11.9%	11.3%	15.4%	13.2%	15.0%	8.8%
Abiomed (Impella heart pumps) sub-franchise — International sales ($M)($M)1	78	97	100	102	86	89	81	77	68	72	67	64
Abiomed (Impella heart pumps) sub-franchise — International operational growth YoY (%)(%)	-6.5%	9.2%	13.9%	25.4%	20.2%	18.4%	23.6%	21.1%	20.1%	25.3%	14.7%	27.1%
Abiomed (Impella heart pumps) sub-franchise — Worldwide reported growth YoY (%)(%)	-2.3%	-2.0%	16.3%	19.8%	16.8%	18.2%	13.3%	12.9%	16.3%	14.5%	14.5%	20.4%
Abiomed (Impella heart pumps) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	-1.5%	-2.0%	14.4%	18.3%	15.6%	16.9%	14.0%	13.2%	16.3%	15.4%	15.0%	20.7%
Abiomed (Impella heart pumps) sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.8%	0.0%	1.9%	1.5%	1.2%	1.3%	-0.7%	-0.3%	0.0%	-0.9%	-0.5%	-0.3%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M)($M)4	325	335	305	318	278	292	258	258	229	77	0	0
Shockwave (intravascular lithotripsy) sub-franchise — U.S. sales ($M)($M)1	261	268	242	238	220	233	206	202	163	77	0	0
Shockwave (intravascular lithotripsy) sub-franchise — U.S. operational growth YoY (%)(%)	18.8%	14.6%	17.8%	18.0%	34.4%
Shockwave (intravascular lithotripsy) sub-franchise — International sales ($M)($M)1	64	67	63	80	59	58	52	56	66	0	0	0
Shockwave (intravascular lithotripsy) sub-franchise — International operational growth YoY (%)(%)	11.2%	15.4%	19.3%	40.7%	-12.4%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide reported growth YoY (%)(%)	16.8%	14.6%	18.5%	23.3%	21.2%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	17.2%	14.7%	18.1%	22.9%	20.9%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.4%	-0.1%	0.4%	0.4%	0.3%
Other Cardiovascular sub-franchise — Worldwide sales ($M)($M)4	81	98	94	95	95	104	103	99	96	93	92	89
Other Cardiovascular sub-franchise — U.S. sales ($M)($M)1	31	33	32	31	30	31	32	31	30	29	30	28
Other Cardiovascular sub-franchise — U.S. operational growth YoY (%)(%)	3.6%	5.5%	0.7%	-0.1%	0.0%	5.4%	7.1%	11.1%	16.7%	12.5%	3.3%
Other Cardiovascular sub-franchise — International sales ($M)($M)1	50	65	62	64	65	72	72	68	66	64	62	61
Other Cardiovascular sub-franchise — International operational growth YoY (%)(%)	-23.1%	-13.2%	-17.5%	-8.8%	-2.5%	11.6%	17.4%	12.3%	7.5%	-1.0%	11.5%
Other Cardiovascular sub-franchise — Worldwide reported growth YoY (%)(%)	-13.9%	-5.7%	-9.1%	-4.6%	-0.7%	10.8%	12.5%	11.8%	10.4%	0.3%	5.7%
Other Cardiovascular sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	-14.7%	-7.5%	-11.9%	-6.1%	-1.7%	9.7%	14.1%	12.0%	10.2%	2.8%	8.8%
Other Cardiovascular sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	0.8%	1.8%	2.8%	1.5%	1.0%	1.1%	-1.6%	-0.2%	0.2%	-2.5%	-3.1%
Surgery Franchise — Worldwide sales ($M)($M)6	2,528	2,653	2,511	2,644	2,542	2,555	2,396	2,507	2,434	2,488	2,416	2,530
Surgery Franchise — U.S. sales ($M)($M)1	1,070	1,094	1,046	1,081	1,031	1,043	1,002	1,038	983	995	987	1,047
Surgery Franchise — U.S. operational growth YoY (%)(%)	3.7%	5.0%	4.4%	4.2%	4.9%	4.8%	1.5%	-0.9%	-1.1%	-2.0%	1.2%	4.6%
Surgery Franchise — International sales ($M)($M)1	1,459	1,559	1,465	1,563	1,511	1,512	1,394	1,469	1,451	1,493	1,429	1,484
Surgery Franchise — International operational growth YoY (%)(%)	-4.2%	0.5%	-1.1%	3.4%	2.2%	-0.2%	0.8%	1.4%	-0.3%	-0.7%	2.3%	7.8%
Surgery Franchise — Worldwide reported growth YoY (%)(%)	-0.6%	3.9%	4.8%	5.5%	4.4%	2.7%	-0.8%	-0.9%	-1.8%	-4.1%	-0.7%	6.1%
Surgery Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	-1.0%	2.3%	1.2%	3.7%	3.3%	1.8%	1.1%	0.4%	-0.7%	-1.2%	1.9%	6.4%
Surgery Franchise — Worldwide currency (FX) impact YoY (%)(%)	0.4%	1.6%	3.6%	1.8%	1.1%	0.9%	-1.9%	-1.3%	-1.1%	-2.9%	-2.6%	-0.3%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide sales ($M)($M)4	1,155	1,189	1,123	1,175	1,165	1,164	1,073	1,151	1,109	1,141	1,087	1,167
Advanced Surgery (endocutters, energy, biosurgicals) — U.S. sales ($M)($M)1	500	499	477	489	477	477	457	478	448	466	446	468
Advanced Surgery (endocutters, energy, biosurgicals) — U.S. operational growth YoY (%)(%)	5.1%	4.7%	4.2%	2.5%	6.2%	2.2%	2.7%	2.0%	-1.4%	0.1%	0.2%	2.5%
Advanced Surgery (endocutters, energy, biosurgicals) — International sales ($M)($M)1	654	691	646	687	688	687	616	673	661	675	641	698
Advanced Surgery (endocutters, energy, biosurgicals) — International operational growth YoY (%)(%)	-5.7%	-1.9%	-1.0%	-0.8%	2.1%	0.2%	-1.0%	-1.6%	-5.1%	-6.4%	-0.7%	7.2%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide reported growth YoY (%)(%)	-0.9%	2.2%	4.6%	2.2%	5.0%	2.0%	-1.2%	-1.4%	-4.7%	-6.7%	-2.8%	5.1%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-1.3%	0.8%	1.2%	0.6%	3.8%	1.0%	0.5%	-0.1%	-3.6%	-3.9%	-0.3%	5.2%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide currency (FX) impact YoY (%)(%)	0.4%	1.4%	3.4%	1.6%	1.2%	1.0%	-1.7%	-1.3%	-1.1%	-2.8%	-2.5%	-0.1%
General Surgery (wound closure / sutures) — Worldwide sales ($M)($M)4	1,373	1,464	1,388	1,468	1,378	1,391	1,323	1,357	1,325	1,346	1,330	1,364
General Surgery (wound closure / sutures) — U.S. sales ($M)($M)1	568	596	569	592	555	567	544	560	535	528	542	579
General Surgery (wound closure / sutures) — U.S. operational growth YoY (%)(%)	2.4%	5.2%	4.5%	5.6%	3.8%	7.2%	0.5%	-3.1%	-0.9%	-3.7%	2.1%	6.4%
General Surgery (wound closure / sutures) — International sales ($M)($M)1	805	868	819	876	823	825	778	795	791	818	788	785
General Surgery (wound closure / sutures) — International operational growth YoY (%)(%)	-3.0%	2.5%	-1.3%	6.9%	2.2%	-0.6%	2.3%	4.0%	4.0%	4.5%	4.8%	8.3%
General Surgery (wound closure / sutures) — Worldwide reported growth YoY (%)(%)	-0.3%	5.2%	4.9%	8.3%	3.9%	3.3%	-0.5%	-0.5%	0.8%	-1.9%	1.0%	7.0%
General Surgery (wound closure / sutures) — Worldwide operational (constant-currency) growth YoY (%)(%)1	-0.8%	3.6%	1.1%	6.3%	2.9%	2.5%	1.6%	1.0%	2.0%	1.2%	3.7%	7.5%
General Surgery (wound closure / sutures) — Worldwide currency (FX) impact YoY (%)(%)	0.5%	1.6%	3.8%	2.0%	1.0%	0.8%	-2.1%	-1.5%	-1.2%	-3.1%	-2.7%	-0.5%
Orthopaedics Franchise — Worldwide sales ($M)($M)8	2,345	2,418	2,383	2,438	2,274	2,305	2,241	2,315	2,191	2,312	2,340	2,268
Orthopaedics Franchise — U.S. sales ($M)($M)1	1,448	1,470	1,435	1,520	1,396	1,420	1,384	1,460	1,359	1,422	1,448	1,425
Orthopaedics Franchise — U.S. operational growth YoY (%)(%)	3.8%	3.5%	3.7%	4.2%	2.7%	-0.2%	-4.4%	2.4%	0.7%	2.5%	6.2%	2.9%
Orthopaedics Franchise — International sales ($M)($M)1	898	948	948	918	878	885	857	856	832	890	892	843
Orthopaedics Franchise — International operational growth YoY (%)(%)	2.9%	5.3%	2.4%	2.3%	1.9%	-4.0%	-0.9%	2.5%	2.2%	4.5%	2.7%	8.8%
Orthopaedics Franchise — Worldwide reported growth YoY (%)(%)	3.2%	4.9%	6.3%	5.3%	3.8%	-0.3%	-4.2%	2.1%	1.2%	2.1%	4.3%	5.6%
Orthopaedics Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	3.4%	4.2%	3.2%	3.5%	2.4%	-1.6%	-3.1%	2.5%	1.3%	3.3%	4.8%	5.0%
Orthopaedics Franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	0.7%	3.1%	1.8%	1.4%	1.3%	-1.1%	-0.4%	-0.1%	-1.2%	-0.5%	0.6%
Hips reconstructive sub-franchise — Worldwide sales ($M)($M)4	419	441	436	439	405	421	409	418	381	417	422	398
Hips reconstructive sub-franchise — U.S. sales ($M)($M)1	271	283	277	284	262	271	263	272	250	265	270	266
Hips reconstructive sub-franchise — U.S. operational growth YoY (%)(%)	3.5%	4.6%	5.2%	4.3%	4.7%	2.1%	-2.5%	2.5%	4.8%	5.8%	12.1%	6.3%
Hips reconstructive sub-franchise — International sales ($M)($M)1	148	158	159	154	144	150	146	146	131	152	152	132
Hips reconstructive sub-franchise — International operational growth YoY (%)(%)	3.0%	3.0%	0.3%	0.4%	5.9%	-4.3%	-0.8%	11.7%	-3.2%	6.8%	3.3%	-3.9%
Hips reconstructive sub-franchise — Worldwide reported growth YoY (%)(%)	3.1%	4.9%	6.5%	4.7%	6.4%	1.0%	-3.1%	5.2%	1.7%	4.9%	8.1%	3.4%
Hips reconstructive sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	3.3%	4.0%	3.5%	2.9%	5.1%	-0.2%	-1.9%	5.6%	1.9%	6.2%	8.7%	2.7%
Hips reconstructive sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	0.9%	3.0%	1.8%	1.3%	1.2%	-1.2%	-0.4%	-0.2%	-1.3%	-0.6%	0.7%
Knees reconstructive sub-franchise — Worldwide sales ($M)($M)4	386	410	420	432	377	389	389	398	352	394	401	387
Knees reconstructive sub-franchise — U.S. sales ($M)($M)1	221	228	239	251	216	226	231	238	212	230	242	242
Knees reconstructive sub-franchise — U.S. operational growth YoY (%)(%)	2.1%	1.1%	3.3%	5.1%	2.1%	-1.9%	-4.3%	-1.5%	2.2%	4.2%	6.9%	4.5%
Knees reconstructive sub-franchise — International sales ($M)($M)1	165	182	181	181	160	164	158	160	140	163	160	144
Knees reconstructive sub-franchise — International operational growth YoY (%)(%)	4.4%	10.3%	6.5%	9.2%	10.9%	-2.9%	2.1%	11.3%	7.0%	17.7%	13.1%	15.6%
Knees reconstructive sub-franchise — Worldwide reported growth YoY (%)(%)	2.5%	5.5%	7.9%	8.6%	7.0%	-1.1%	-3.0%	3.1%	4.0%	8.4%	9.0%	9.2%
Knees reconstructive sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	3.1%	5.0%	4.6%	6.8%	5.6%	-2.3%	-1.7%	3.3%	4.1%	9.5%	9.3%	8.4%
Knees reconstructive sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.6%	0.5%	3.3%	1.8%	1.4%	1.2%	-1.3%	-0.2%	-0.1%	-1.1%	-0.3%	0.8%
Trauma extremities sub-franchise — Worldwide sales ($M)($M)4	844	827	833	813	793	768	772	764	761	759	765	741
Trauma extremities sub-franchise — U.S. sales ($M)($M)1	555	536	532	543	512	501	502	514	497	498	504	487
Trauma extremities sub-franchise — U.S. operational growth YoY (%)(%)	8.6%	6.7%	6.1%	5.6%	3.0%	0.7%	-0.5%	5.5%	1.8%	3.0%	2.8%	3.6%
Trauma extremities sub-franchise — International sales ($M)($M)1	288	291	301	270	281	267	270	250	265	260	261	255
Trauma extremities sub-franchise — International operational growth YoY (%)(%)	2.8%	7.4%	3.1%	2.7%	2.5%	-1.5%	7.2%	-0.5%	4.8%	5.5%	-1.1%	4.1%
Trauma extremities sub-franchise — Worldwide reported growth YoY (%)(%)	6.4%	7.6%	8.0%	6.4%	4.2%	1.2%	0.9%	3.0%	2.6%	2.8%	1.0%	4.4%
Trauma extremities sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	6.5%	6.9%	5.0%	4.7%	2.9%	-0.1%	2.1%	3.5%	2.8%	3.8%	1.4%	3.8%
Trauma extremities sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.1%	0.7%	3.0%	1.7%	1.3%	1.3%	-1.2%	-0.5%	-0.2%	-1.0%	-0.4%	0.6%
Spine, Sports & Other sub-franchise — Worldwide sales ($M)($M)4	697	740	694	756	698	727	671	735	696	743	752	742
Spine, Sports & Other sub-franchise — U.S. sales ($M)($M)1	401	423	387	442	406	422	388	434	400	430	432	430
Spine, Sports & Other sub-franchise — U.S. operational growth YoY (%)(%)	-1.2%	0.2%	-0.1%	1.9%	1.3%	-1.7%	-10.2%	1.1%	-3.6%	-0.8%	6.5%	-0.7%
Spine, Sports & Other sub-franchise — International sales ($M)($M)1	296	317	307	312	293	305	283	300	296	314	320	311
Spine, Sports & Other sub-franchise — International operational growth YoY (%)(%)	2.0%	1.9%	0.7%	-0.7%	-4.8%	-6.4%	-8.9%	-2.9%	0.4%	-2.9%	0.9%	16.5%
Spine, Sports & Other sub-franchise — Worldwide reported growth YoY (%)(%)	-0.1%	1.8%	3.5%	2.8%	0.3%	-2.1%	-10.8%	-0.9%	-1.9%	-3.1%	3.2%	6.2%
Spine, Sports & Other sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	0.1%	0.9%	0.2%	0.8%	-1.3%	-3.7%	-9.7%	-0.6%	-2.0%	-1.7%	4.0%	5.8%
Spine, Sports & Other sub-franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.2%	0.9%	3.3%	2.0%	1.6%	1.6%	-1.1%	-0.3%	0.1%	-1.4%	-0.8%	0.4%
Vision Franchise — Worldwide sales ($M)($M)6	1,461	1,451	1,365	1,420	1,400	1,369	1,279	1,303	1,300	1,285	1,258	1,208
Vision Franchise — U.S. sales ($M)($M)1	596	565	579	531	571	557	566	509	549	523	547	487
Vision Franchise — U.S. operational growth YoY (%)(%)	4.3%	1.4%	2.4%	4.3%	4.2%	6.5%	3.4%	4.5%	7.2%	-1.2%	-1.8%	6.8%
Vision Franchise — International sales ($M)($M)1	865	887	785	889	828	813	713	794	751	763	710	721
Vision Franchise — International operational growth YoY (%)(%)	5.6%	8.5%	4.6%	8.5%	7.5%	3.4%	3.9%	12.2%	1.8%	2.2%	-1.1%	6.4%
Vision Franchise — Worldwide reported growth YoY (%)(%)	4.4%	6.0%	6.7%	8.9%	7.7%	6.5%	1.7%	7.9%	3.5%	-1.7%	-3.3%	5.5%
Vision Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1	5.1%	5.6%	3.6%	6.8%	6.1%	4.6%	3.7%	9.1%	4.0%	0.8%	-1.4%	6.6%
Vision Franchise — Worldwide currency (FX) impact YoY (%)(%)	-0.7%	0.4%	3.1%	2.1%	1.6%	1.9%	-2.0%	-1.2%	-0.5%	-2.5%	-1.9%	-1.1%
Contact Lenses / Other (ACUVUE) — Worldwide sales ($M)($M)4	1,053	1,025	969	1,008	1,018	965	919	937	968	918	910	882
Contact Lenses / Other (ACUVUE) — U.S. sales ($M)($M)1	465	445	468	417	456	429	452	396	441	409	438	374
Contact Lenses / Other (ACUVUE) — U.S. operational growth YoY (%)(%)	1.9%	3.6%	3.7%	5.3%	3.5%	4.8%	3.1%	6.0%	10.2%	0.2%	-1.4%	8.9%
Contact Lenses / Other (ACUVUE) — International sales ($M)($M)1	588	580	501	592	562	536	467	541	527	509	472	508
Contact Lenses / Other (ACUVUE) — International operational growth YoY (%)(%)	6.2%	7.9%	1.7%	5.3%	3.4%	1.4%	2.4%	8.5%	0.6%	1.2%	-3.1%	7.2%
Contact Lenses / Other (ACUVUE) — Worldwide reported growth YoY (%)(%)	3.5%	6.1%	5.5%	7.6%	5.2%	5.1%	1.0%	6.3%	4.2%	-2.2%	-4.6%	6.1%
Contact Lenses / Other (ACUVUE) — Worldwide operational (constant-currency) growth YoY (%)(%)1	4.3%	6.0%	2.7%	5.3%	3.5%	2.9%	2.7%	7.4%	4.7%	0.7%	-2.3%	7.9%
Contact Lenses / Other (ACUVUE) — Worldwide currency (FX) impact YoY (%)(%)	-0.8%	0.1%	2.8%	2.3%	1.7%	2.2%	-1.7%	-1.1%	-0.5%	-2.9%	-2.3%	-1.8%
Surgical Vision (intraocular lenses / cataract) — Worldwide sales ($M)($M)4	408	426	396	411	383	403	361	365	333	367	348	326
Surgical Vision (intraocular lenses / cataract) — U.S. sales ($M)($M)1	132	120	111	113	116	128	114	113	108	113	110	114
Surgical Vision (intraocular lenses / cataract) — U.S. operational growth YoY (%)(%)	13.6%	-6.0%	-2.9%	0.6%	7.0%	12.6%	4.3%	-0.4%	-3.6%	-5.8%	-3.7%	0.4%
Surgical Vision (intraocular lenses / cataract) — International sales ($M)($M)1	276	306	285	297	266	277	246	252	225	254	238	212
Surgical Vision (intraocular lenses / cataract) — International operational growth YoY (%)(%)	4.3%	9.6%	10.1%	15.3%	17.1%	7.3%	7.1%	21.1%	4.7%	4.5%	3.4%	4.7%
Surgical Vision (intraocular lenses / cataract) — Worldwide reported growth YoY (%)(%)	6.8%	5.6%	9.7%	12.4%	14.9%	9.9%	3.7%	12.4%	1.3%	-0.5%	0.3%	3.7%
Surgical Vision (intraocular lenses / cataract) — Worldwide operational (constant-currency) growth YoY (%)(%)1	7.1%	4.7%	6.0%	10.8%	13.8%	8.9%	6.2%	13.6%	1.9%	1.2%	1.1%	3.1%
Surgical Vision (intraocular lenses / cataract) — Worldwide currency (FX) impact YoY (%)(%)	-0.3%	0.9%	3.7%	1.6%	1.1%	1.0%	-2.5%	-1.2%	-0.6%	-1.7%	-0.8%	0.6%

Total segment income before tax ($M)($M)3	5,842	7,426	6,556	5,259	7,733	6,756	6,631	4,081	5,541	6,548	6,489	4,642
Innovative Medicine segment income before tax ($M)($M)4	5,066	6,249	5,317	5,058	6,446	5,552	5,210	4,009	4,482	5,459	4,969	4,238
Innovative Medicine — Cost of products sold ($M)($M)	4,486	4,296	4,390	3,976	3,672	3,978	4,020	3,514	3,549	3,603	3,370
Innovative Medicine — Selling, marketing and administrative expenses ($M)($M)	3,035	3,130	2,918	3,456	2,869	2,789	2,261	3,312	2,491	2,665	2,438
Innovative Medicine — Research and development expense ($M)($M)	3,888	2,875	2,813	3,466	2,944	2,869	2,548	3,698	4,213	2,722	2,896
Innovative Medicine — Other segment expense/(income), net ($M)($M)	282	-166	-12	-193	-368	14	-166	-201	-155	41	-111
MedTech segment income before tax ($M)($M)4	776	1,177	1,239	201	1,287	1,204	1,421	72	1,059	1,089	1,520	404
MedTech — Cost of products sold ($M)($M)	3,597	3,737	3,701	3,973	3,612	3,638	3,326	3,596	3,381	3,248	3,120
MedTech — Selling, marketing and administrative expenses ($M)($M)	3,014	3,069	2,906	3,035	2,801	2,862	2,656	2,836	2,723	2,671	2,582
MedTech — Research and development expense ($M)($M)	764	778	714	786	728	647	677	1,600	739	718	646
MedTech — Other segment expense/(income), net ($M)($M)	491	165	76	806	2	190	-60	84	-11	231	-47
Consolidated earnings before provision for taxes on income ($M)($M)	34	6,747	5,990	4,966	7,493	6,491	13,631	3,887	3,338	5,748	3,714	4,826
Consolidated total assets ($M)($M)4	197,425	201,061	200,894	199,210	192,816	193,389	193,671	180,104	178,287	181,088	171,966	167,558
Total segment identifiable assets ($M)($M)	165,158	165,437	164,297	164,539	160,924	162,232	143,838	141,392				133,034
Innovative Medicine identifiable assets ($M)($M)	78,944	78,856	78,118	78,057	74,422	75,487	58,727	57,070				58,324
MedTech identifiable assets ($M)($M)	86,214	86,581	86,179	86,482	86,502	86,745	85,111	84,322				74,710
General corporate / unallocated assets ($M)($M)	32,267	35,624	36,597	34,671	31,892	31,157	49,833	38,712				34,524
Additions to property, plant and equipment — Consolidated ($M)($M)4	1,362	1,321	1,049	1,837	1,157	1,043	795	1,612	1,029	976	807
Total segment additions to PP&E ($M)($M)	1,303	1,246	1,017	1,737	1,082	1,002	756	1,553	973	902	725
Innovative Medicine additions to PP&E ($M)($M)	704	653	508	910	479	411	276	739	418	321	232
MedTech additions to PP&E ($M)($M)	599	593	509	827	603	591	480	814	555	581	493
General corporate additions to PP&E ($M)($M)	59	75	32	100	75	41	39	59	56	74	82
Depreciation and amortization — Consolidated ($M)($M)4	2,117	1,959	2,004	2,011	1,777	1,943	1,772	1,896	1,846	1,782	1,815	1,843
Total segment depreciation and amortization ($M)($M)	2,053	1,904	1,939	1,941	1,718	1,883	1,720	1,834	1,750	1,656	1,757
Innovative Medicine depreciation and amortization ($M)($M)	800	800	1,036	1,015	600	800	884	967	700	700	1,011	1,647
MedTech depreciation and amortization ($M)($M)	500	500	903	926	500	500	836	867	500	400	746	1,843
General corporate depreciation and amortization ($M)($M)	64	55	65	70	59	60	52	62	96	126	58
Goodwill — Consolidated carrying value ($M)($M)2	48,474	48,479	48,558	48,772	48,048	48,117	44,468	44,200	44,799	44,250	36,616	36,558
Innovative Medicine goodwill ($M)($M)	14,748	14,755	14,812	14,967	14,268	14,326	10,907	10,692	11,112	10,768	10,552	10,407
MedTech goodwill ($M)($M)	33,726	33,724	33,746	33,805	33,780	33,791	33,561	33,508	33,687	33,482	26,064	26,151

Non-GAAP adjusted earnings before provision for taxes on income ($M)($M)2	7,672	8,660	7,821	7,046	8,436	8,188	8,011	5,421	7,277	8,404	7,877	6,237
Non-GAAP adjusted pre-tax profit margin (% to sales)(%)	30.2%	34.2%	32.5%	28.7%	35.2%	34.5%	36.6%	24.1%	32.4%	37.4%	36.8%	29.2%
Non-GAAP adjusted pre-tax earnings growth YoY (%)(%)	-9.1%	5.8%	-2.4%	30.0%	15.9%	-2.6%	1.7%	-13.1%	-9.4%	5.0%	4.5%	-3.8%
Non-GAAP adjusted net earnings ($M)($M)5	6,339	7,081	6,614	6,009	6,801	6,699	6,706	4,946	5,876	6,840	6,580	5,562
Non-GAAP adjusted net profit margin (% to sales)(%)	25.0%	28.0%	27.5%	24.5%	28.3%	28.2%	30.6%	22.0%	26.1%	30.5%	30.8%	26.0%
Non-GAAP adjusted net earnings growth YoY (%)(%)	-6.8%	5.7%	-1.4%	21.5%	15.7%	-2.1%	1.9%	-11.1%	-13.3%	1.6%	3.8%	2.4%
Pre-tax Non-GAAP adjustment — Intangible asset amortization expense ($M)($M)	1,240	1,245	1,247	1,186	1,048	1,267	1,120	1,171	1,171	1,106	1,078	1,148
Pre-tax Non-GAAP adjustment — Litigation-related expense/(gain), net ($M)($M)	5,519	267	330	854	15	57	-6,966	-16	2,388	352	2,726	166
Pre-tax Non-GAAP adjustment — Restructuring-related expense ($M)($M)	195	276	62	210	168	79	55	62	47	-11	171	139
Non-GAAP adjusted diluted net earnings per share ($)($)2	2.59	2.90	2.70	2.46	2.80	2.77	2.77	2.04	2.42	2.82	2.71	2.29
Operational (constant-currency) adjusted diluted EPS ($)($)	2.61	2.86	2.57	2.35	2.72	2.71	2.81	2.05	2.41	2.82	2.72	2.28
Non-GAAP adjusted diluted EPS growth YoY (%)(%)	-7.5%	4.7%	-2.5%	20.6%	15.7%	-1.8%	2.2%	-10.9%	-9.0%	10.2%	12.4%	11.7%
Non-GAAP adjusted effective tax rate (%)(%)1	17.4%	18.2%	15.4%	14.7%	19.4%	18.2%	16.3%	8.8%	19.3%	18.6%	16.5%	10.8%
GAAP effective tax rate (%)(%)	-517.6%	18.0%	12.6%	-3.0%	31.2%	14.7%	19.3%	11.7%	19.3%	18.5%	12.4%	14.4%
GAAP gross profit ($M)($M)6	17,302	17,259	15,956	16,596	16,690	16,115	14,536	15,392	15,508	15,578	14,872	14,597
GAAP gross profit margin (% to sales)(%)	68.1%	68.2%	66.3%	67.6%	69.6%	67.9%	66.4%	68.4%	69.0%	69.4%	69.6%	68.2%
Cost of products sold (% to sales)(%)	31.9%	31.8%	33.7%	32.4%	30.4%	32.1%	33.6%	31.6%	31.0%	30.6%	30.4%	31.8%
Selling, marketing and administrative expenses (% to sales)(%)	24.7%	25.4%	25.1%	27.5%	24.7%	24.8%	23.3%	28.6%	24.3%	25.3%	24.6%	27.1%
Research and development expense (% to sales)(%)	18.3%	14.4%	14.7%	17.3%	15.3%	14.8%	14.7%	23.5%	22.0%	15.3%	16.6%	20.9%
GAAP earnings before provision for taxes (% to sales)(%)	0.1%	26.7%	24.9%	20.2%	31.2%	27.3%	62.3%	17.3%	14.9%	25.6%	17.4%	22.6%
GAAP net earnings margin (% to sales)(%)	0.8%	21.9%	21.8%	20.8%	21.5%	23.3%	50.2%	15.2%	12.0%	20.9%	15.2%	19.3%
Full-Year Guidance — Estimated reported sales midpoint ($B)4	101.20	101.10	100.80	100.50	93.70	93.40	91.40	89.60	88.60	88.20	88.20	88.20
Full-Year Guidance — Estimated reported sales growth midpoint (%)(%)	7.4%	7.3%	7.0%	6.7%	5.7%	5.4%	3.1%	1.0%	5.4%	5.0%	5.0%	5.0%
Full-Year Guidance — Operational sales midpoint ($B)	100.70	100.60	100.20	100.00	93.20	92.90	92.00	91.30	89.60	89.40	88.00	88.60
Full-Year Guidance — Operational sales growth midpoint (%)(%)	6.9%	6.8%	6.4%	6.2%	5.1%	4.8%	3.8%	3.0%	6.6%	6.4%	5.8%	5.5%
Full-Year Guidance — Adjusted operational sales growth ex-A&D midpoint (%)(%)	6.6%	6.5%	6.1%	5.9%	3.8%	3.5%	2.5%	2.5%	6.0%	5.8%	5.8%	5.5%
Full-Year Guidance — Adjusted diluted EPS midpoint ($)($)3	11.10	11.68	11.55	11.53	10.85	10.85	10.60	10.60	9.93	10.02	10.65	10.65
Full-Year Guidance — Adjusted diluted EPS growth midpoint (%)(%)	2.9%	8.2%	7.1%	6.9%	8.7%	8.7%	6.2%	6.2%	0.1%	1.0%	7.4%	7.4%
Full-Year Guidance — Adjusted operational diluted EPS midpoint ($)($)	11	11.58	11.40	11.38	10.68	10.68	10.60	10.85	9.91	10.05	10.68	10.65
Full-Year Guidance — Adjusted operational diluted EPS growth midpoint (%)(%)	2.0%	7.3%	5.7%	5.5%	7.0%	7.0%	6.2%	8.7%	0.1%	1.3%	7.7%	7.4%

Accrued rebates, returns and promotions (GTN) liability on balance sheet ($M)($M)	18,936	19,990	18,399	19,124	21,356	20,823	18,780	17,580	18,439	17,539	16,182	16,001
Restructuring expense ($M)($M)	181	34	32	84	63	64	17	42	41	-13	164	56

Total inventories, net ($M)($M)3	15,377	15,144	14,583	14,191	14,146	13,412	12,659	12,444	12,603	12,169	11,383	11,181
Raw materials and supplies ($M)($M)	2,483	2,515	2,612	2,530	2,552	2,389	2,371	2,337	2,545	2,407	2,331	2,355
Goods in process ($M)($M)	3,930	4,224	4,033	3,828	3,763	3,971	3,203	2,815	2,989	2,556	2,172	1,952
Finished goods ($M)($M)	8,964	8,405	7,938	7,833	7,831	7,052	7,085	7,292	7,069	7,206	6,880	6,874
Property, plant and equipment, net ($M)($M)2	24,104	23,582	23,270	23,169	22,338	21,949	20,871	20,518	20,479	19,748	19,632	19,898
Property, plant and equipment, gross ($M)($M)	55,472	55,518	54,695	54,364	53,375	52,472	49,884	48,768	49,274	48,035	47,585	47,776
Less: Accumulated depreciation ($M)($M)	31,368	31,936	31,425	31,195	31,037	30,523	29,013	28,250	28,795	28,287	27,953	27,878
Intangible assets, net (excluding goodwill) ($M)($M)3	46,652	48,229	49,061	50,403	48,737	49,835	36,755	37,618	39,490	39,725	34,286	34,175
Finite-lived intangible assets, net ($M)2
Patents and trademarks, net ($M)($M)	25,899	24,815	25,576	26,649	22,687	22,516	17,843	18,571	18,227	18,603	14,372	15,609
Other finite-lived intangibles, net ($M)($M)	5,688	5,949	6,184	6,363	6,469	7,423	6,611	6,766	7,209	7,158	7,188	7,637
Finite-lived intangible assets, gross ($M)2
Patents and trademarks, gross ($M)($M)	60,575	58,542	58,515	59,156	54,026	53,272	45,591	44,695	44,926	43,438	39,198	40,417
Other finite-lived intangibles, gross ($M)($M)	21,153	21,283	21,340	21,361	21,179	21,910	20,493	20,310	20,715	20,176	19,930	20,322
Intangible asset amortization expense ($M)($M)4	1,200	1,200	1,200	1,200	1,000	1,300	1,100	1,100	1,200	1,100	1,100	1,100
Estimated future intangible amortization — Year 1 ($M)($M)	4,400	4,400	4,400	5,100	4,000	4,000	3,400	4,000	3,900	3,900	3,500	4,300
Estimated future intangible amortization — Year 2 ($M)($M)	3,700	3,700	3,700	4,400	3,300	3,400	2,800	3,400	3,300	3,300	2,900	3,500
Estimated future intangible amortization — Year 3 ($M)($M)	3,600	3,600	3,600	3,700	2,600	2,700	2,200	2,800	2,700	2,700	2,300	2,900
Estimated future intangible amortization — Year 4 ($M)($M)	3,500	3,500	3,500	3,600	2,500	2,600	2,200	2,200	2,000	2,000	1,600	2,300

Total long-term debt (including current maturities) ($M)1
Long-term debt, noncurrent ($M)($M)	35,799	37,344	37,527	39,438	39,408	39,235	38,355	30,651	31,289	31,636	25,082	25,881
Cash dividends paid to shareholders ($M)($M)4	3,227	3,227	3,131	3,131	3,132	3,129	2,989	2,984	2,985	2,985	2,869	2,865
Cash dividends paid per share ($)($)	1.34	1.34	1.30		1.30	1.30	1.24		1.24	1.24	1.19
Common stock repurchases ($M)($M)	1,712	219	-4,034	1,922	1,904	-2	2,129	257	539	136	1,475	216
Treasury stock shares held (M shares)	712.73	711.62	713.26	711.90	713.65	713.06	714.22	712.92	712.54	713.00	713.12	712.76
Treasury stock carrying value ($M)($M)	76,184	75,863	76,264	75,624	75,887	75,713	75,906	75,680	75,619	75,689	75,710	75,662
Stock-based compensation expense ($M)($M)	357	458	300	355	347	410	288	262	295	341	302	116

U.S. Producer Price Index (PPI) — Pharmaceutical Preparation Manufacturing (PCU325412325412)2	929.06	926.72	925.44	919.12	917.42	915.09	915.34	918.11	917.27	914.37	907.84	896.32
U.S. Consumer Price Index (CPI) — Medical Care Commodities (CUSR0000SAM1)	404.94	410.39	416.81		417.00	416.48	415.97	412.57	415.90	414.52	408.35	410.06
U.S. Consumer Price Index (CPI) — Medical Care Services (CUUR0000SAM2)	654.45	651.42	648.16		638.15	631.04	623.98	618.85	612.81	611.70	606.32	597.15

114 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Fiscal calendar: Johnson & Johnson operates on a 52/53-week fiscal year ending on the Sunday nearest December 31 (FY2025 ended December 28, 2025; Q1 2026 ended March 29, 2026; Q2 2026 ended June 28, 2026; Q3 2026 ended September 27, 2026).
Core operational & financial KPIs (Groups 1–6) cover: (1) Consolidated & Geographic Revenue Disaggregation ($25,399M in Q3 2026 / $94,193M in FY25 across U.S. $14,959M and International $10,440M [Europe $5,405M, Asia-Pacific/Africa $3,650M, Western Hemisphere ex-U.S. $1,385M]) and Reported (+5.9%), Operational Constant-Currency (+6.0%), Currency FX (-0.1%), and Adjusted Operational ex-A&D (+6.1%) growth drivers across all regions; (2–3) Innovative Medicine Segment ($16,757M in Q3 2026 / $60,401M in FY25, +7.9% operational in Q3 2026) across all 6 Therapeutic Areas — Oncology ($7,602M in Q3 2026, +16.7% operational: DARZALEX $4,239M, ERLEADA $1,023M, CARVYKTI $710M, IMBRUVICA $563M, RYBREVANT/LAZCLUZE $320M, TECVAYLI $312M, TALVEY $171M, legacy ZYTIGA & VELCADE), Immunology ($4,221M: TREMFYA $2,396M, STELARA $716M, SIMPONI/SIMPONI ARIA $568M, REMICADE $394M including U.S. Exports), Neuroscience ($2,375M: INVEGA SUSTENNA/TRINZA $998M, SPRAVATO $624M, CAPLYTA $398M, CONCERTA $143M, legacy RISPERDAL CONSTA), Pulmonary Hypertension ($897M: UPTRAVI $483M, OPSUMIT/OPSYNVI $372M, legacy TRACLEER), Infectious Diseases ($813M: EDURANT $386M, PREZISTA/SYMTUZA $381M, legacy COVID-19 Vaccine), and Cardiovascular/Metabolism ($849M: XARELTO $653M, legacy INVOKANA & PROCRIT/EPREX) — each disaggregated by Worldwide, U.S., and International ($M and operational YoY %); (4) MedTech Segment ($8,642M in Q3 2026 / $33,792M in FY25, +2.5% operational) across Cardiovascular ($2,307M: Electrophysiology $1,487M, Abiomed $412M, Shockwave $325M), Surgery ($2,528M: Advanced $1,155M, General $1,373M), Orthopaedics ($2,345M: Trauma $844M, Spine/Sports & Other $697M, Hips $419M, Knees $386M), and Vision ($1,461M: Contact Lenses $1,053M, Surgical $408M), plus legacy Consumer Health franchises prior to the FY23Q3 Kenvue separation; (5) Segment Pre-Tax Income, Significant Segment Expenses under ASU 2023-07 (COGS, SM&A, R&D, Other), Identifiable Assets, CapEx, D&A, and Goodwill; and (6) Non-GAAP Adjusted Pre-Tax Profit ($7,672M / 30.2% margin in Q3 2026), Adjusted Net Earnings ($6,339M / 25.0% margin), Adjusted Diluted EPS ($2.59 in Q3 2026; $10.79 in FY25), Operational Adjusted EPS ($2.61), Adjusted Effective Tax Rate (17.4%), GAAP % to Sales ratios, and Full-Year 2026 Management Guidance ($101.2B reported sales / $11.10 adjusted EPS midpoint).
Groups 7–11 cover: (7) Balance Sheet Accrued Rebates, Returns & Promotions (GTN) Liability ($18,864M at Q3 2026), Major Wholesaler Revenue Concentration (Cencora 31.3%, McKesson 21.8%, Cardinal Health 12.6% in FY25), Advertising ($1,800M in FY25), Shipping & Handling (% of sales), and Restructuring; (8) Inventories by Stage ($13,517M net at Q3 2026: Raw Materials $1,943M, WIP $3,581M, Finished Goods $7,993M), PP&E by Category ($22,226M net at Q3 2026), Geographic PP&E across U.S., Europe, APAC/Africa & Western Hemisphere, Intangible Assets ($35,882M net at Q3 2026 with 5-year amortization schedule), and Operating Leases; (9) Debt & 5-Year Maturity Schedule ($39,719M total long-term debt at Q3 2026), Dividends ($3,275M / $1.35 per share in Q3 2026), Share Repurchases, Stock-Based Compensation, Deferred Tax Assets/Liabilities by Attribute, and Unrecognized Tax Benefits ($3,904M at FY25); (10) Global Workforce (140,800 employees / 138,200 FTEs in 10-K; 139,769 in HRIS across 4 regions), L&D Spend ($128M) & Training Hours (33.8 hrs/employee), CEO Pay Ratio (360:1 / $91,000 median employee in FY25), Form 11-K J&J Savings Plan ($26.89B net assets / $51.46B Master Trust in FY25), and Defined Benefit Pension ($29,572M PBO / $35,914M plan assets / +$6,342M funded status at FY25) & Postretirement Plans; and (11) Assured ESG & Sustainability Metrics from the 2025 Health for Humanity Report & Form SD (Community Giving $5,543M, 200M VERMOX doses, $16.2B Global Tax Contribution, 407 regulatory / 29 FDA inspections, 0.25 TRIR, Scope 1/2/3 GHG emissions, 100% renewable electricity, Water, Waste, 39,825 suppliers / $32.3B spend, and 218 in-scope 3TG suppliers / 340 verified SORs).
No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Data updated 2026-10-25.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Consolidated Revenue, Geographic Disaggregation & Constant-Currency Growth Drivers

Consolidated sales to customers ($M) ($M)72 periods

Innovative Medicine — Oncology & Immunology Therapeutic Areas & Key Drugs

Innovative Medicine Segment Total — Worldwide sales ($M) ($M)43 periods

Johnson & Johnson (JNJ) operating KPIs

KPIs

Every KPI on its own page

Consolidated Revenue, Geographic Disaggregation & Constant-Currency Growth Drivers

Innovative Medicine — Oncology & Immunology Therapeutic Areas & Key Drugs

Innovative Medicine — Neuroscience, Pulmonary Hypertension, Infectious Diseases & CVM

MedTech Franchises & Sub-Franchises (Plus Legacy Consumer Health)

Segment Profitability, Significant Segment Expenses (ASU 2023-07), Assets, CapEx & D&A

Non-GAAP Adjusted Earnings, Statement of Earnings Ratios (% to Sales) & Full-Year Guidance

Gross-to-Net (GTN) Rebates Liability, Wholesaler Concentration, Advertising & Restructuring

Manufacturing, Inventories, PP&E, Geographic Long-Lived Assets, Intangibles & Leases

Debt, Maturities, Capital Allocation, Share Repurchases & Income Taxes

Workforce, Executive Compensation, Form 11-K Savings Plan & Defined Benefit Pensions

ESG, Global Health Access, Environmental Stewardship, Quality/FDA & Supply Chain

Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements